PubMed Health⌕ Search

Biomedical subjects

T Kanko

Publications and source records attributed to T Kanko.

9 recordsLinked to original sources
PubMed1990

[Combination chemotherapy of non-small cell lung cancer (NSCLC) with cisplatin (CDDP), carboquone (CQ) and prednisolone (PDN)(PPQ therapy)].

Twenty-five courses (twenty-two pts) with NSCLC have been entered in the trial evaluating the combination of CDDP 20 mg/m2 i.v. day 1, 2, 3, 4, 5, CQ 7 mg/m2 i.v. day 1, and PS 30 mg/body per os day 1, 2, 3, 4, 5, repeated every 4 weeks. Except for 1 case of early death, judgement of efficacy was possible in 24 courses, including one case of squamous cell carcinoma and 23 cases of adenocarcinoma. CR was obtained in no cases and PR in 7 cases, all of which were adenocarcinoma, with an efficacy rate of 29%. Response for primary site was obtained in 4 of 22 cases (18%). Median survival time of the 22 cases was 11.5 months. Main side effects of PPQ Therapy were symptoms in digestive organs such as nausea and loss of appetite, and bone marrow inhibition. Renal dysfunction was controllable by measures to cope with diuresis.

Adenocarcinoma↗
PubMed1990

[Lymphocyte subset change during cancer chemotherapy on patients with gastrointestinal, lung and hematopoietic malignancies].

Lymphocyte subsets measured by Ortho-mune on OKT 3, OKT 4A, OKT 8, OKT 10, OKT 11, OKM1, OKB 7, OKB 2 and OKDR were observed before and after chemotherapy on patients with gastrointestinal, lung and hematopoietic malignancies. Almost all patients showed decreased T-cell function expressed by OKT 11 or OKT 3 and suppressor, helper T-cell function expressed by OKT 8 and OKT 4A. In some patients improvement of T-cell function were observed with clinical response and in such cases life span seemed to be longer as expected, and it is supposed that during cancer chemotherapy improvement of T-cell function expressed by OKT series may be important prognostic factors.

Adult↗
PubMed1984

[Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].

A phase II study of KW 2083 [7-N-(p-Hydroxyphenyl)-Mitomycin C] was carried out in 14 cases of stomach cancer, 5 of lung cancer, 5 of colon cancer and 5 other types of cancer. KW 2083 was intravenously injected at a dose of 40 mg/body weekly in 26 cases. Among 23 evaluable cases, partial response was obtained in 6 cases (26%). The PR cases were 4 of stomach cancer and 2 of lung cancer, the former being all undifferentiated adenocarcinoma. Regarding hematologic toxicities, thrombocytopenia was the most principal toxicity and an important weak point of KW 2083. Thrombocytopenia (less than 75,000/mm3) was observed in 13 cases (50%). Recovery took about 4 weeks, but by that time 3 cases had still not recovered to 75,000/mm3. leukocytopenia (less than 3,000/mm3) was observed in 17 cases (65%). Concerning gastrointestinal symptoms, anorexia occurred in 11 cases (42%), nausea and vomiting in 11 cases (42%), diarrhea in 1 case and stomatitis in 1 case. T1/2 (beta-phase) of KW 2083 was half that of Mitomycin C.

Adolescent↗
PubMed1979

Multidrug combination in cancer chemotherapy: MFU therapy.

Three-drug therapy with Mitomycin-C (MMC), 5-fluorouracil (5-FU), and a nitrosourea derivative, ACNU, was carried out in 72 cases of carcinoma patients, mostly of stomach carcinoma. 1) According to Karnofsky's criteria, an effect of above I-A was observed in 10 of 35 cases (29%) treated with MFU-I (0.08 mg/kg of MMC, 10 mg/kg of 5-FU and 0.4-0.8 mg/kg of ACNU twice a week for the first two weeks and once a week thereafter for a total of six weeks as one course), 5 of 14 cases (36%) with MFU-I-O (MFU-I plus 0.2-2.0 KE of OK-432 i.m. three times a week), and 6 of 20 cases (30%) with MFU-II (0.2 mg/kg of MMC once in two weeks, 5 mg/kg of 5-FU every day, 2 mg/kg of ACNU once in six weeks as one course). 2) According to the criteria of the group of Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare, a partial response was seen in 29% of the cases treated with MFU-I, in 38% of the cases treated with MFU-I-O, and 30% of the cases treated with MFU-II. 3) Side effect was slight in the digestive organs but the bone marrow suppression was remarkable. Leukopenia and thrombocytopenia were seen in the majority of patients under treatment. The hematological side effect appeared early in MFU-II therapy, but it was not severe and recovered quickly. Combined use of OK-432 seemed to be effective to shorten the period of hematological disorders. Thus, three-drug combination treatment with MMC, 5-FU, and ACNU seems to be useful for patients with malignant tumor, chiefly of the digestive organs. Especially, MFU-II treatment schedule seems to be a combination therapy that has relatively small hematological side effects.

Drug Therapy, Combination↗
PubMed1978

Clinical experiences with aclacinomycin-A.

Aclacinomycin is a new anthracycline analog of adriamycin and daunomycin. Aclacinomycin contains three sugars. The drug has been studied in 22 cases in a phase 1 type of trial on a schedule 20 mg i.v. every other day up to a total of 300 mg. Toxicity has consisted of myelosuppression, nausea and vomiting, and transient hepatic disturbances. Evidence of clinical activity was observed in several cases including a case of breast cancer and gastric cancer. Although no full patial remissions were recorded, further study is continuing.

Animals↗